Viral Resistance Analyses From the Remdesivir Phase 3 Adaptive COVID-19 Treatment Trial-1 (ACTT-1)

Published on
Journal: Nanoscale
[저자] Charlotte Hedskog, Lauren Rodriguez, Pavitra Roychoudhury, Meei-Li Huang, Keith R Jerome, Linhui Hao, Renee C Ireton, Jiani Li, Jason K Perry, Dong Han, Gregory Camus, Alexander L Greninger, Michael Gale, Danielle P Porter
[Category] update2024,
PMC URL    Pubmed URL    DOI URL    [DOI] 10.1093/infdis/jiad270    
[Article Type] Major Article
[Source] PMC

In participants with COVID-19 enrolled in a phase 3 clinical trial of remdesivir, similar rates of emergent amino acid substitutions were observed for remdesivir and placebo. Substitutions were associated with low to no change in viral susceptibility to remdesivir.

All Keywords
【저자키워드】 COVID-19, SARS-CoV-2, Remdesivir, resistance, RNA-dependent RNA polymerase,